ATN 021b Therapeutic Agents History Form [CRF 3] Dataset in Prevalence of Morphologic and Metabolic Abnormalities in HIV Infected and Uninfected Young Men

Data from Therapeutic Agents History Form [CRF 3]
Study Description
A multi-center, cross-sectional study of HIV infected and uninfected males, ages 12 to 24, that evaluated the prevalence and severity of morphologic and metabolic abnormalities in HIV-infected young men and assessed the drug and non-drug factors related to these abnormalities. Differences in glucose metabolism, lipids, lactate, body composition, and bone density between HIV infected and uninfected young men were assessed to understand the pathophysiological effects of protease inhibitor (PI)-based and non-nucleoside reverse transcriptase inhibitor (NNRTI)-based therapies in young men. One study visit conducted over 1 or more days included survey questionnaires, DEXA scanning, collection of blood and urine specimens, anthropometric measurements, and blood tests examining glucose and lipid metabolism and levels of C-Reactive protein and lactate. Biospecimens are available. HIV infected and uninfected males, ages 12 to 24, of Tanner Stage 4 or 5

治疗史记录表[CRF 3]相关数据
研究概况
本研究为多中心横断面研究，纳入12至24岁的HIV感染与未感染男性群体，旨在评估HIV感染青年男性的形态学与代谢异常的患病率及严重程度，并分析与这类异常相关的药物及非药物影响因素。
本研究对比了HIV感染与未感染青年男性在葡萄糖代谢、血脂、乳酸、身体成分及骨密度方面的差异，以明确以蛋白酶抑制剂（PI）和非核苷类逆转录酶抑制剂（NNRTI）为基础的治疗方案对青年男性的病理生理效应。
单次研究访视时长覆盖1天及以上，内容包含问卷调查、双能X线吸收法（DEXA）扫描、血液与尿液标本采集、人体测量学指标检测，以及针对葡萄糖与脂代谢、C反应蛋白及乳酸水平的血液检测项目。
本研究可提供生物标本。
研究对象为坦纳分期（Tanner Stage）4或5期的12至24岁HIV感染与未感染男性。